Drug Profile
Research programme: dermatological therapeutics - Novabiotics/Malvern Cosmeceutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Malvern Cosmeceutics; NovaBiotics
- Class Lipoproteins; Peptides; Polymers
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Skin disorders
Highest Development Phases
- No development reported Acne; Rosacea; Skin disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rosacea in United Kingdom (Topical)
- 16 Jul 2016 No recent reports of development identified for research development in Acne in United Kingdom (Topical)
- 16 Jul 2016 No recent reports of development identified for research development in Skin-disorders in United Kingdom (Topical)